Evidence map›Paper›PMID 39986440›Full record

ReviewAdvanced drug delivery reviews2025

PhotoChem Interplays: Lighting the Way for Drug Delivery and Diagnosis.

Asmita Banstola, Zuan-Tao Lin, Yongli Li, Mei X Wu

Abstract readReview
In one paragraph

Review in Advanced drug delivery reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asmita BanstolaWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Department of Dermatology, Harvard Medical School (HMS), Boston, MA 02114, USA.
Zuan-Tao LinWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Department of Dermatology, Harvard Medical School (HMS), Boston, MA 02114, USA.
Yongli LiWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Department of Dermatology, Harvard Medical School (HMS), Boston, MA 02114, USA.
Mei X WuWellman Center for Photomedicine, Massachusetts General Hospital (MGH), Department of Dermatology, Harvard Medical School (HMS), Boston, MA 02114, USA. Electronic address: mwu5@mgh.harvard.edu.

Funding

Biomimetic nanoparticles to enhance the breadth of influenza vaccinesR01AI146588 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WU, MEI X · 2020 to 2024
$1.5M
A novel bacteria-specific pro-photosensitizerR21AI183486 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WU, MEI X · 2024 to 2025
$457k
NIAID NIH HHS R01 AI146588NIAID NIH HHS R21 AI183486
6 · The paper itself

Abstract

Light, a non-invasive tool integrated with cutting-edge nanotechnologies, has driven transformative advancements in imaging-based diagnosis and drug delivery for cancer and bacterial treatments. This review discusses recent progress in these areas, beginning with emerging imaging technologies. Unlike traditional photosensors activated by visible light, alternative energy sources such as near-infrared (NIR) light, X-rays, and ultrasound have been extensively investigated to activate various photosensors, achieving high sensitivity, wavelength versatility, and spatial resolution for deep-tissue imaging. Moreover, to address challenges like tissue autofluorescence in real-time fluorescence imaging, afterglow luminescent nanoparticles are being developed by integrating these alternative energy sources for real-time imaging and sensing in deep tissue for precise cancer diagnosis and treatment beyond superficial tissues. In addition to deep tissue imaging, light-responsive nanomedicines are revolutionizing anticancer and antimicrobial phototherapy by enabling spatially and temporally controlled drug release. These smart nanoparticles are engineered to release therapeutic cargo at target sites in response to microenvironmental cues specific to tumors or infections. In anticancer phototherapy, these nanoparticles facilitate controlled drug release via photoisomerization, photothermal, and photodynamic processes. To enhance circulation time and specific targeting, biomimetic nanoparticles, which mimic natural anti-tumor responses by our body, have attracted increasing attention. In antimicrobial phototherapy, research has been focused on the chemical modification of the photosensitizer to enable targeted drug delivery. An intriguing strategy has recently emerged involving the development of "pro-photosensitizers" that are specifically activated within bacterial cells upon light irradiation, offering a high margin of safety. These advancements leverage photochemical reactions and nanotechnology to enhance precision therapy and diagnosis in addressing critical health challenges.

Indexed as

Drug Delivery SystemsNeoplasmsAnimalsHumansLightNanoparticlesPhotochemotherapyAfterglowBiomimetic nanoparticlesPhotoisomerizationPhoto-sensingPhotosensitizerPro-photosensitizers

Identifiers

PMID39986440
PMCPMC11903148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.